Recent advances in ligand targeted therapy

Journal of Drug Targeting

Volumn 20, Issue 1, 2012, Pages 1-22

  Trapani, Giuseppe ^a   Denora, Nunzio ^a   Trapani, Adriana ^a   Laquintana, Valentino ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

endocytosis; Receptor mediated targeting; selective delivery; targeted nanocarriers

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMOXICILLIN; ANTIMITOTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARABINOGALACTAN; AVIDIN; BIOTIN; CHOLESTEROL; CLARITHROMYCIN; CYTARABINE; DENDRIMER; DOXORUBICIN; FOLATE RECEPTOR; LECTIN RECEPTOR; LIGAND; LIPOSOME; MACROGOL; METHOTREXATE; NANOCARRIER; PACLITAXEL; PEMETREXED; PENTETIC ACID; POLYAMIDOAMINE; POLYGLACTIN; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TRANSFERRIN RECEPTOR; TUBULYSIN A; TUBULYSIN B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER THERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; EXPERIMENTAL MODEL; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; HUMAN; LIGAND TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOTECHNOLOGY; NEOPLASMS; NERVOUS SYSTEM DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 83155164537     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.611518     Document Type: Review

References (116)

1. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C. (2006). In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci, 29, 367-374. (Pubitemid 44709858)
2. Anbharasi V, Cao N, Feng SS. (2010). Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res A, 94, 730-743.
3. Arote RB, Hwang SK, Lim HT, Kim TH, Jere D, Jiang HL, Kim YK, Cho MH, Cho CS. (2010). The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model. Biomaterials, 31, 2435-2445.
4. Askoxylakis V, Zitzmann-Kolbe S, Zoller F, Altmann A, Markert A, Rana S, Marr A, Mier W, Debus J, Haberkorn U. (2011). Challenges in optimizing a prostate carcinoma binding peptide, identified through the phage display technology. Molecules, 16, 1559-1578.
5. Balestrieri ML, Napoli C. (2007). Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer, 43, 1242-1250. (Pubitemid 46729702)
6. Barbas AS, Mi J, Clary BM, White RR. (2010). Aptamer applications for targeted cancer therapy. Future Oncol, 6, 1117-1126.
7. Bies C, Lehr CM, Woodley JF. (2004). Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev, 56, 425-435. (Pubitemid 38210415)
8. Birn H, Nielsen S, Christensen EI. (1997). Internalization and apicalto- basolateral transport of folate in rat kidney proximal tubule. Am J Physiol, 272, F70-F78. (Pubitemid 27382281)
9. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. (2001). In-vivo measurement of activated microglia in dementia. Lancet, 358, 461-467. (Pubitemid 32769854)
10. Chandna P, Khandare JJ, Ber E, Rodriguez-Rodriguez L, Minko T. (2010). Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm Res, 27, 2296-2306.
11. Chen X, Plasencia C, Hou Y, Neamati N. (2005). Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem, 48, 1098-1106. (Pubitemid 40270453)
12. Cheng Y, Zak O, Aisen P, Harrison SC, Walz T. (2004). Structure of the human transferrin receptor-transferrin complex. Cell, 116, 565-576. (Pubitemid 38264433)
13. Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. (2006). Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release, 112, 199-207.
14. Choi CH, Alabi CA, Webster P, Davis ME. (2010). Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA, 107, 1235-1240.
15. Das M, Mohanty C, Sahoo SK. (2009). Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv, 6, 285-304.
16. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-1070.
17. De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. (2009). Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res, 42, 873-880.
18. Decaudin D. (2004). Peripheral benzodiazepine receptor and its clinical targeting. Anticancer Drugs, 15, 737-745. (Pubitemid 39281296)
19. Dominska M, Dykxhoorn DM. (2010). Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci, 123, 1183-1189.
20. Dosio F, Arpicco S, Stella B, Brusa P, Cattel L. (2009). Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm, 382, 117-123.
21. Dowlati A, Loo M, Bury T, Fillet G, Beguin Y. (1997). Soluble and cell-associated transferrin receptor in lung cancer. Br J Cancer, 75, 1802-1806. (Pubitemid 27230707)
22. Dube D, Khatri K, Goyal AK, Mishra N, Vyas SP. (2010). Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin. Drug Dev Ind Pharm, 36, 547-555.
23. Elnakat H, Ratnam M. (2004). Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev, 56, 1067-1084. (Pubitemid 38496508)
24. Fischgräbe J, Wülfing P. (2008). Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol, 3, 85-98.
25. Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. (2010). Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol, 66, 43-52.
26. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. (2006). In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in idiopathic Parkinsons disease. Neurobiol Dis, 21, 404-412. (Pubitemid 43099863)
27. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer R S, Farokhzad OC. 2007. Targeted nanoparticles for cancer therapy. Nano Today, 2, 14-21. (Pubitemid 46672835)
28. Gullotti E, Yeo Y. (2009). Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm, 6, 1041-1051.
29. Gunawan RC, Auguste DT. (2010). The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes. Biomaterials, 31, 900-907.
30. Guo KT, Ziemer G, Paul A, Wendel HP. (2008). CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci, 9, 668-678. (Pubitemid 351631122)
31. Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM. (2001). Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol, 48, 169-176. (Pubitemid 32710229)
32. Heath VL, Bicknell R. (2009). Anticancer strategies involving the vasculature. Nat Rev Clin Oncol, 6, 395-404.
33. Herbst SM, Klegerman ME, Kim H, Qi J, Shelat H, Wassler M, Moody MR, Yang CM, Ge X, Zou Y, Kopechek JA, Clubb FJ, Kraemer DC, Huang S, Holland CK, McPherson DD, Geng YJ. (2010). Delivery of stem cells to porcine arterial wall with echogenic liposomes conjugated to antibodies against CD34 and intercellular adhesion molecule-1. Mol Pharm, 7, 3-11.
34. Hicke BJ, Stephens AW. (2000). Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest, 106, 923-928.
35. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. (2007). Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J, 21, 1117-1125. (Pubitemid 46495701)
36. Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY. (2007). Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug Chem, 18, 41-49. (Pubitemid 46145993)
37. Jin Y, Liu S, Yu B, Golan S, Koh CG, Yang J, Huynh L, Yang X, Pang J, Muthusamy N, Chan KK, Byrd JC, Talmon Y, Lee LJ, Lee RJ, Marcucci G. (2010). Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. Mol Pharm, 7, 196-206.
38. Kakimoto S, Moriyama T, Tanabe T, Shinkai S, Nagasaki T. (2007). Dual-ligand effect of transferrin and transforming growth factor alpha on polyethyleneimine-mediated gene delivery. J Control Release, 120, 242-249. (Pubitemid 47058638)
39. Kang H, Donoghue MB, Liu H, Tan W. (2010). A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb), 46, 249-251.
40. Kim D, Jeong YY, Jon S. (2010). A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano, 4, 3689-3696.
41. Kim YK, Choi JY, Jiang HL, Arote R, Jere D, Cho MH, Je YH, Cho CS. (2009). Hybrid of baculovirus and galactosylated PEI for efficient gene carrier. Virology, 387, 89-97.
42. Krishna AD, Mandraju RK, Kishore G, Kondapi AK. (2009). An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS ONE, 4, e7240.
43. Kularatne SA, Low PS. (2010). Targeting of nanoparticles: folate receptor. Methods Mol Biol, 624, 249-265.
44. Lam JK, Armes SP, Lewis AL, Stolnik S. (2009). Folate conjugated phosphorylcholine-based polycations for specific targeting in nucleic acids delivery. J Drug Target, 17, 512-523.
45. Laquintana V, Denora N, Musacchio T, Lasorsa M, Latrofa A, Trapani G. (2009). Peripheral benzodiazepine receptor ligand-PLGA polymer conjugates potentially useful as delivery systems of apoptotic agents. J Control Release, 137, 185-195.
46. Lee CC, Grandinetti G, McLendon PM, Reineke TM. (2010). A polycation scaffold presenting tunable click sites: conjugation to carbohydrate ligands and examination of hepatocyte-targeted pDNA delivery. Macromol Biosci, 10, 585-598.
47. Lee RJ, Low PS. (1994). Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem, 269, 3198-3204. (Pubitemid 24237629)
48. Lee RJ, Wang S, Low PS. (1996). Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim Biophys Acta, 1312, 237-242. (Pubitemid 26246522)
49. Lehr CM. (2000). Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release, 65, 19-29.
50. Li X, Ding L, Xu Y, Wang Y, Ping Q. (2009). Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm, 373, 116-123.
51. Liu J, Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, Kong D. (2011). Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J Nanomedicine, 6, 59-69.
52. Liu S. (2008). Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev, 60, 1347-1370.
53. Low PS, Kularatne SA. (2009). Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol, 13, 256-262.
54. Lu Y, Wu J, Wu J, Gonit M, Yang X, Lee A, Xiang G, Li H, Liu S, Marcucci G, Ratnam M, Lee RJ. (2007). Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm, 4, 707-712. (Pubitemid 350004270)
55. McIntyre GD, Scott CF Jr, Ritz J, Blättler WA, Lambert JM. (1994). Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents. Bioconjug Chem, 5, 88-97. (Pubitemid 2043895)
56. McPherson PS, Kay BK, Hussain NK. (2001). Signaling on the endocytic pathway. Traffic, 2, 375-384. (Pubitemid 32574004)
57. Mezo G, Manea M. (2010). Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv, 7, 79-96.
58. Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B. (2009). Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Int J Pharm, 379, 293-300.
59. Müller C, Mindt TL, de Jong M, Schibli R. (2009). Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy. Eur J Nucl Med Mol Imaging, 36, 938-946.
60. Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP. (2009). PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm, 6, 468-479.
61. Nakamura J, Nakajima N, Matsumura K, Hyon SH. (2010). Watersoluble taxol conjugates with dextran and targets tumor cells by folic acid immobilization. Anticancer Res, 30, 903-909.
62. Onyüksel H, Mohanty PS, Rubinstein I. (2009). VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17- demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm, 365, 157-161.
63. Ortner A, Wernig K, Kaisler R, Edetsberger M, Hajos F, Köhler G, Mosgoeller W, Zimmer A. (2010). VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J Drug Target, 18, 457-467.
64. Pan X, Guan J, Yoo JW, Epstein AJ, Lee LJ, Lee RJ. (2008). Cationic lipidcoated magnetic nanoparticles associated with transferrin for gene delivery. Int J Pharm, 358, 263-270.
65. Pan XQ, Wang H, Lee RJ. (2003). Antitumor activity of folate receptortargeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res, 20, 417-422. (Pubitemid 36288371)
66. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. (2006). Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci, 27, 402-409. (Pubitemid 44069585)
67. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem, 338, 284-293. (Pubitemid 40312593)
68. Pasqualini R, Koivunen E, Ruoslahti E. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol, 15, 542-546. (Pubitemid 27251571)
69. Pastan I, Willingham MC. (1985). The Pathway of Endocytosis. New York: Plenum Press.
70. Paulos CM, Turk MJ, Breur GJ, Low PS. (2004). Folate receptormediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev, 56, 1205-1217. (Pubitemid 38496516)
71. Pilkington GJ, Parker K, Murray SA. (2008). Approaches to mitochondrially mediated cancer therapy. Semin Cancer Biol, 18, 226-235.
72. Pinhassi RI, Assaraf YG, Farber S, Stark M, Ickowicz D, Drori S, Domb AJ, Livney YD. (2010). Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules, 11, 294-303.
73. Prabaharan M, Grailer JJ, Steeber DA, Gong S. (2009). Thermosensitive micelles based on folate-conjugated poly(N-vinylcaprolactam)- block-poly(ethylene glycol) for tumor-targeted drug delivery. Macromol Biosci, 9, 744-753.
74. Pulkkinen M, Pikkarainen J, Wirth T, Tarvainen T, Haapa-aho V, Korhonen H, Seppälä J, Järvinen K. (2008). Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur J Pharm Biopharm, 70, 66-74.
75. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. (2009). Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori. J Drug Target, 17, 225-234.
76. Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, Westrick E, Klein PJ, Wang Y, Vlahov IR, Leamon CP. (2009). In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol Pharm, 6, 1518-1525.
77. Sabharanjak S, Mayor S. (2004). Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev, 56, 1099-1109. (Pubitemid 38496510)
78. Sahoo SK, Labhasetwar V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2, 373-383. (Pubitemid 41503678)
79. Samuelson LE, Dukes MJ, Hunt CR, Casey JD, Bornhop DJ. (2009). TSPO targeted dendrimer imaging agent: synthesis, characterization, and cellular internalization. Bioconjug Chem, 20, 2082-2089.
80. Sanz L, Qiao J, Vile RG, Alvarez-Vallina L. (2005). Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Curr Gene Ther, 5, 63-70. (Pubitemid 40246741)
81. Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J, Duncan R. (1991). N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer, 63, 859-866.
82. Simard P, Leroux JC. (2009). pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int J Pharm, 381, 86-96.
83. Srinivasan R, Marchant RE, Gupta AS. (2010). In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J Biomed Mater Res A, 93, 1004-1015.
84. Stein BS, Bensch KG, Sussman HH. (1984). Complete inhibition of transferrin recycling by monensin in K562 cells. J Biol Chem, 259, 14762-14772. (Pubitemid 15222205)
85. Stahl P, Schwartz AL. (1986). Receptor-mediated endocytosis. J Clin Invest, 77, 657-662. (Pubitemid 16067934)
86. Sudheesh MS, Jain V, Shilakari G, Kohli DV. (2009). Development and characterization of lectin-functionalized vesicular constructs bearing amphotericin B for bio-film targeting. J Drug Target, 17, 148-158.
87. Taratula O, Garbuzenko OB, Kirkpatrick P, Pandya I, Savla R, Pozharov VP, He H, Minko T. (2009). Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release, 140, 284-293.
88. Terada K, Manchikalapudi P, Noiva R, Jauregui HO, Stockert RJ, Schilsky ML. (1995). Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. J Biol Chem, 270, 20410-20416.
89. Thomas M, Kularatne SA, Qi L, Kleindl P, Leamon CP, Hansen MJ, Low PS. (2009). Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann N Y Acad Sci, 1175, 32-39.
90. Trapani G, Laquintana V, Latrofa A, Ma J, Reed K, Serra M, Biggio G, Liso G, Gallo JM. (2003). Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors. Bioconjug Chem, 14, 830-839. (Pubitemid 36875445)
91. Tu X, Zang L, Lan D, Liang W. (2009). Screening and identification of a peptide specifically targeted to NCI-H1299 cells from a phage display peptide library. Mol Med Report, 2, 1005-1010.
92. Van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. (2011). Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release, 150, 30-36.
93. Vandewalle B, Granier AM, Peyrat JP, Bonneterre J, Lefebvre J. (1985). Transferrin receptors in cultured breast cancer cells. J Cancer Res Clin Oncol, 110, 71-76. (Pubitemid 15030766)
94. Venneti S, Lopresti BJ, Wiley CA. (2006). The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol, 80, 308-322. (Pubitemid 46107737)
95. Wang H, Ross JF, Ratnam M. (1998). Structure and regulation of a polymorphic gene encoding folate receptor type gamma/gamma. Nucleic Acids Res, 26, 2132-2142. (Pubitemid 28291757)
96. Wang H, Zhao P, Liang X, Gong X, Song T, Niu R, Chang J. (2010). Folate- PEG coated cationic modified chitosan-cholesterol liposomes for tumor-targeted drug delivery. Biomaterials, 31, 4129-4138.
97. Willingham MC, Pastan I. (1980). The receptosome: an intermediate organelle of receptor mediated endocytosis in cultured fibroblasts. Cell, 21, 67-77. (Pubitemid 10040056)
98. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. (2006). A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther, 317, 1372-1381. (Pubitemid 43764144)
99. Wu J, Liu Q, Lee RJ. 2006. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm; 316: 148-153. (Pubitemid 43786219)
100. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. (2010). Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release, 143, 136-142.
101. Zhang Y, Sun Y, Xu X, Zhang X, Zhu H, Huang L, Qi Y, Shen YM. (2010). Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates. J Med Chem, 53, 3262-3272.
102. Zhang Y, Sun Y, Xu X, Zhu H, Huang L, Zhang X, Qi Y, Shen YM. (2010). Radiosynthesis and micro-SPECT imaging of 99mTc-dendrimer poly(amido)-amine folic acid conjugate. Bioorg Med Chem Lett, 20, 927-931.
103. Zhang Y, Thomas TP, Desai A, Zong H, Leroueil PR, Majoros IJ, Baker JR. (2010). Targeted dendrimeric anticancer prodrug: A methotrexatefolic acid-poly(amidoamine) conjugate and a novel, rapid, one pot synthetic approach. Bioconjugate Chem, 21, 489-95.
104. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. (2010). Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm, 74, 467-473.
105. Zhao X, Li H, Lee RJ. (2008). Targeted drug delivery via folate receptors. Expert Opin Drug Deliv, 5, 309-319. (Pubitemid 351454380)
106. Zhao R, Min SH, Wang Y, Campanella E, Low PS, Goldman ID. (2009). A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Biol Chem, 284, 4267-4274.
107. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. (2007). Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folatereceptor- targeted liposomes. J Pharm Sci, 96, 2424-2435. (Pubitemid 47477897)
108. Zheng Y, Cai Z, Song X, Yu B, Bi Y, Chen Q, Zhao D, Xu J, Hou S. (2009). Receptor mediated gene delivery by folate conjugated N-trimethyl chitosan in vitro. Int J Pharm, 382, 262-269.
109. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. (2009). A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood, 113, 438-446.
110. Xiang G, Wu J, Lu Y, Liu Z, Lee RJ. (2008). Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int J Pharm, 356, 29-36.
111. Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y. (2008). Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res, 14, 8161-8168.
112. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, Sakaguchi S. (2007). Control of immune responses by antigenspecific regulatory T cells expressing the folate receptor. Immunity, 27, 145-159. (Pubitemid 47089022)
113. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. (2006). Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA, 103, 13872-13877. (Pubitemid 44414000)
114. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. (2007). Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther, 321, 462-468. (Pubitemid 46624512)
115. Yang SJ, Lin FH, Tsai KC, Wei MF, Tsai HM, Wong JM, Shieh MJ. (2010). Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconjug Chem, 21, 679-689.
116. Yu W, Zhang N, Li C. (2009). Saccharide modified pharmaceutical nanocarriers for targeted drug and gene delivery. Curr Pharm Des, 15, 3826-3836.